首页 > 最新文献

Regenerative Therapy最新文献

英文 中文
Effect of a FOXO1 inhibitor on trophoblast differentiation from human pluripotent stem cells and ERV-associated gene expression FOXO1 抑制剂对人类多能干细胞滋养层分化和 ERV 相关基因表达的影响
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.08.020
Erika Tanaka , Michiyo Koyanagi-Aoi , So Nakagawa , Sayumi Shimode , Hideto Yamada , Yoshito Terai , Takashi Aoi

Introduction

In human placental development, the trophectoderm (TE) appears in blastocysts on day 5 post-fertilization and develops after implantation into three types of trophoblast lineages: cytotrophoblast (CT), syncytiotrophoblast (ST), and extravillous trophoblast (EVT). CDX2/Cdx2 is expressed in the TE, and Cdx2 expression is upregulated by knockdown of Foxo1 in mouse ESCs. However, the significance of FOXO1 in trophoblast lineage differentiation during the early developmental period remains unclear. In this study, we examined the effect of FOXO1 inhibition on the differentiation of naive human induced pluripotent stem cells (iPSCs) into TE and trophoblast lineages.

Methods

We induced TE differentiation from naive iPSCs in the presence or absence of a FOXO1 inhibitor, and the resulting cells were subjected to trophoblast differentiation procedures without the FOXO1 inhibitor. The cells obtained in these processes were assessed for morphology, gene expression, and hCG secretion using phase-contrast microscopy, reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR (RT-qPCR), RNA-seq, immunochromatography, and a chemiluminescent enzyme immunoassay.

Results

In the induction of trophoblast differentiation from naive iPSCs, treatment with a FOXO1 inhibitor resulted in the enhanced expression of TE markers, CDX2 and HAND1, but conversely decreased the expression of ST markers, such as ERVW1 (Syncytin-1) and GCM1, and an EVT marker, HLA-G. The proportion of cells positive for an early TE marker TACSTD2 and negative for a late TE marker ENPEP was higher in FOXO1 inhibitor-treated cells than in non-treated cells. The expressions of ERVW1 (Syncytin-1), ERVFRD-1 (Syncytin-2), and other endogenous retrovirus (ERV)-associated genes that have been reported to be expressed in trophoblasts were suppressed in the cells obtained by differentiating the TE cells treated with FOXO1 inhibitor.

Conclusions

Treatment with a FOXO1 inhibitor during TE induction from naive iPSCs promotes early TE differentiation but hinders the progression of differentiation into ST and EVT. The suppression of ERV-associated genes may be involved in this process.

引言在人类胎盘发育过程中,受精后第 5 天胚泡中出现滋养层(TE),着床后发育成三种类型的滋养层:细胞滋养层(CT)、合胞滋养层(ST)和胚外滋养层(EVT)。CDX2/Cdx2在TE中表达,在小鼠ESC中敲除Foxo1可上调Cdx2的表达。然而,FOXO1 在发育早期滋养层细胞系分化中的意义仍不清楚。在这项研究中,我们考察了FOXO1抑制对天真人诱导多能干细胞(iPSCs)向TE和滋养层母细胞系分化的影响。方法我们在有或没有FOXO1抑制剂的情况下诱导天真iPSCs向TE分化,并在没有FOXO1抑制剂的情况下对得到的细胞进行滋养层母细胞分化程序。使用相衬显微镜、逆转录聚合酶链反应(RT-PCR)、定量 RT-PCR (RT-qPCR)、RNA-seq、免疫层析和化学发光酶免疫测定评估了这些过程中获得的细胞的形态、基因表达和 hCG 分泌情况。结果 在诱导天真 iPSCs 滋养细胞分化的过程中,使用 FOXO1 抑制剂会增强 TE 标记(CDX2 和 HAND1)的表达,但反之会降低 ST 标记(如 ERVW1(Syncytin-1)和 GCM1)以及 EVT 标记(HLA-G)的表达。经 FOXO1 抑制剂处理的细胞中,早期 TE 标记 TACSTD2 阳性、晚期 TE 标记 ENPEP 阴性的细胞比例高于未处理的细胞。在用 FOXO1 抑制剂处理的 TE 细胞分化得到的细胞中,ERVW1(Syncytin-1)、ERVFRD-1(Syncytin-2)和其他已报道在滋养细胞中表达的内源性逆转录病毒(ERV)相关基因的表达受到抑制。ERV相关基因的抑制可能参与了这一过程。
{"title":"Effect of a FOXO1 inhibitor on trophoblast differentiation from human pluripotent stem cells and ERV-associated gene expression","authors":"Erika Tanaka ,&nbsp;Michiyo Koyanagi-Aoi ,&nbsp;So Nakagawa ,&nbsp;Sayumi Shimode ,&nbsp;Hideto Yamada ,&nbsp;Yoshito Terai ,&nbsp;Takashi Aoi","doi":"10.1016/j.reth.2024.08.020","DOIUrl":"10.1016/j.reth.2024.08.020","url":null,"abstract":"<div><h3>Introduction</h3><p>In human placental development, the trophectoderm (TE) appears in blastocysts on day 5 post-fertilization and develops after implantation into three types of trophoblast lineages: cytotrophoblast (CT), syncytiotrophoblast (ST), and extravillous trophoblast (EVT). CDX2/Cdx2 is expressed in the TE, and Cdx2 expression is upregulated by knockdown of Foxo1 in mouse ESCs. However, the significance of FOXO1 in trophoblast lineage differentiation during the early developmental period remains unclear. In this study, we examined the effect of FOXO1 inhibition on the differentiation of naive human induced pluripotent stem cells (iPSCs) into TE and trophoblast lineages.</p></div><div><h3>Methods</h3><p>We induced TE differentiation from naive iPSCs in the presence or absence of a FOXO1 inhibitor, and the resulting cells were subjected to trophoblast differentiation procedures without the FOXO1 inhibitor. The cells obtained in these processes were assessed for morphology, gene expression, and hCG secretion using phase-contrast microscopy, reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR (RT-qPCR), RNA-seq, immunochromatography, and a chemiluminescent enzyme immunoassay.</p></div><div><h3>Results</h3><p>In the induction of trophoblast differentiation from naive iPSCs, treatment with a FOXO1 inhibitor resulted in the enhanced expression of TE markers, CDX2 and HAND1, but conversely decreased the expression of ST markers, such as ERVW1 (Syncytin-1) and GCM1, and an EVT marker, HLA-G. The proportion of cells positive for an early TE marker TACSTD2 and negative for a late TE marker ENPEP was higher in FOXO1 inhibitor-treated cells than in non-treated cells. The expressions of ERVW1 (Syncytin-1), ERVFRD-1 (Syncytin-2), and other endogenous retrovirus (ERV)-associated genes that have been reported to be expressed in trophoblasts were suppressed in the cells obtained by differentiating the TE cells treated with FOXO1 inhibitor.</p></div><div><h3>Conclusions</h3><p>Treatment with a FOXO1 inhibitor during TE induction from naive iPSCs promotes early TE differentiation but hinders the progression of differentiation into ST and EVT. The suppression of ERV-associated genes may be involved in this process.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 729-740"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001561/pdfft?md5=e231e861dc5c09a1e4c13c29d81d1944&pid=1-s2.0-S2352320424001561-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An ADSC-loaded dermal regeneration template promotes full-thickness wound healing 装载 ADSC 的真皮再生模板可促进全厚伤口愈合
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.08.010
Jin Xu , Xuelian Chen , Jizhuang Wang , Beibei Zhang , Wenjia Ge , Jiaqiang Wang , Peilang Yang , Yan Liu

Introduction

Full-thickness wounds lead to delayed wound healing and scarring. Adipose-derived stem cell (ADSC) grafting promotes wound healing and minimizes scarring, but the low efficiency of grafting has been a challenge. We hypothesized that loading ADSCs onto a clinically widely used dermal regeneration template (DRT) would improve the efficacy of ADSC grafting and promote full-thickness wound healing.

Methods

ADSCs from human adipose tissue were isolated, expanded, and labeled with a cell tracker. Labeled ADSCs were loaded onto the DRT. The viability, the location of ADSCs on the DRT, and the abundance of ADSCs in the wound area were confirmed using CCK8 and fluorescence microscopy. Full-thickness wounds were created on Bama minipigs, which were applied with sham, ADSC, DRT, and ADSC-DRT. Wounds from the four groups were collected at the indicated time and histological analysis was performed. RNA-seq analysis was also conducted to identify transcriptional differences among the four groups. The identified genes by RNA-seq were verified by qPCR. Immunohistochemistry and western blotting were used to assess collagen deposition. In vitro, the supernatant of ADSCs was used to culture fibroblasts to investigate the effect of ADSCs on fibroblast transformation into myofibroblasts.

Results

ADSCs were successfully isolated, marked, and loaded onto the DRT. The abundance of ADSCs in the wound area was significantly greater in the ADSC-DRT group than in the ADSC group. Moreover, the ADSC-DRT group exhibited better wound healing with improved re-epithelialization and denser collagen deposition than the other three groups. The RNA-seq results suggested that the application of the integrated ADSC-DRT system resulted in the differential expression of genes mainly associated with extracellular matrix remodeling. In vivo, wounds from the ADSC-DRT group exhibited an earlier increase in type III collagen deposition and alleviated scar formation. ADSCs inhibited the transformation of fibroblasts into myofibroblasts, along with increased levels of CTGF, FGF, and HGF in the supernatant of ADSCs. Wounds from the ADSC-DRT group had up-regulated expressions of CTGF, HGF, FGF, and MMP3.

Conclusion

The integral of ADSC-DRT increased the efficacy of ADSC grafting, and promoted full-thickness wound healing with better extracellular matrix remodeling and alleviated scar formation.

导言:全厚伤口会导致伤口延迟愈合和疤痕形成。脂肪来源干细胞(ADSC)移植可促进伤口愈合并减少疤痕,但移植效率低一直是个难题。我们假设,将 ADSCs 植入临床上广泛使用的真皮再生模板(DRT)将提高 ADSC 移植的效果,促进全厚伤口愈合。将标记的 ADSCs 装入 DRT。使用 CCK8 和荧光显微镜确认 ADSCs 的存活率、在 DRT 上的位置以及伤口区域 ADSCs 的数量。在巴马小猪身上创建全厚伤口,分别使用假体、ADSC、DRT 和 ADSC-DRT。在指定时间收集四组伤口并进行组织学分析。此外,还进行了 RNA-seq 分析,以确定四组之间的转录差异。通过 qPCR 验证了 RNA-seq 确定的基因。免疫组织化学和 Western 印迹法用于评估胶原沉积。在体外,用 ADSCs 的上清液培养成纤维细胞,研究 ADSCs 对成纤维细胞转化为肌成纤维细胞的影响。ADSC-DRT组伤口区域的ADSC数量明显高于ADSC组。此外,与其他三组相比,ADSC-DRT 组的伤口愈合更好,再上皮化程度更高,胶原沉积更致密。RNA-seq结果表明,ADSC-DRT整合系统的应用导致了主要与细胞外基质重塑相关的基因的差异表达。在体内,ADSC-DRT 组伤口的 III 型胶原沉积增加较早,疤痕形成也有所缓解。ADSCs 抑制了成纤维细胞向肌成纤维细胞的转化,同时 ADSCs 上清液中的 CTGF、FGF 和 HGF 水平也有所提高。ADSC-DRT组伤口的CTGF、HGF、FGF和MMP3表达上调。结论ADSC-DRT的整合提高了ADSC移植的疗效,促进了伤口的全厚愈合,细胞外基质重塑效果更好,并缓解了疤痕的形成。
{"title":"An ADSC-loaded dermal regeneration template promotes full-thickness wound healing","authors":"Jin Xu ,&nbsp;Xuelian Chen ,&nbsp;Jizhuang Wang ,&nbsp;Beibei Zhang ,&nbsp;Wenjia Ge ,&nbsp;Jiaqiang Wang ,&nbsp;Peilang Yang ,&nbsp;Yan Liu","doi":"10.1016/j.reth.2024.08.010","DOIUrl":"10.1016/j.reth.2024.08.010","url":null,"abstract":"<div><h3>Introduction</h3><p>Full-thickness wounds lead to delayed wound healing and scarring. Adipose-derived stem cell (ADSC) grafting promotes wound healing and minimizes scarring, but the low efficiency of grafting has been a challenge. We hypothesized that loading ADSCs onto a clinically widely used dermal regeneration template (DRT) would improve the efficacy of ADSC grafting and promote full-thickness wound healing.</p></div><div><h3>Methods</h3><p>ADSCs from human adipose tissue were isolated, expanded, and labeled with a cell tracker. Labeled ADSCs were loaded onto the DRT. The viability, the location of ADSCs on the DRT, and the abundance of ADSCs in the wound area were confirmed using CCK8 and fluorescence microscopy. Full-thickness wounds were created on Bama minipigs, which were applied with sham, ADSC, DRT, and ADSC-DRT. Wounds from the four groups were collected at the indicated time and histological analysis was performed. RNA-seq analysis was also conducted to identify transcriptional differences among the four groups. The identified genes by RNA-seq were verified by qPCR. Immunohistochemistry and western blotting were used to assess collagen deposition. In vitro, the supernatant of ADSCs was used to culture fibroblasts to investigate the effect of ADSCs on fibroblast transformation into myofibroblasts.</p></div><div><h3>Results</h3><p>ADSCs were successfully isolated, marked, and loaded onto the DRT. The abundance of ADSCs in the wound area was significantly greater in the ADSC-DRT group than in the ADSC group. Moreover, the ADSC-DRT group exhibited better wound healing with improved re-epithelialization and denser collagen deposition than the other three groups. The RNA-seq results suggested that the application of the integrated ADSC-DRT system resulted in the differential expression of genes mainly associated with extracellular matrix remodeling. In vivo, wounds from the ADSC-DRT group exhibited an earlier increase in type III collagen deposition and alleviated scar formation. ADSCs inhibited the transformation of fibroblasts into myofibroblasts, along with increased levels of CTGF, FGF, and HGF in the supernatant of ADSCs. Wounds from the ADSC-DRT group had up-regulated expressions of CTGF, HGF, FGF, and MMP3.</p></div><div><h3>Conclusion</h3><p>The integral of ADSC-DRT increased the efficacy of ADSC grafting, and promoted full-thickness wound healing with better extracellular matrix remodeling and alleviated scar formation.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 800-810"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001470/pdfft?md5=921b9cad842d8220b310a82be82f0523&pid=1-s2.0-S2352320424001470-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Status and prospects for the development of regenerative therapies for corneal and ocular diseases 角膜和眼部疾病再生疗法的发展现状和前景
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.09.001
Hiroshi Takayanagi , Ryuhei Hayashi

Among the regenerative therapies being put into clinical use, the field of corneal regenerative therapy is one of the most advanced, with several regulatory approved products. This article describes the progress from initial development through to clinical application in the eye field, with a particular focus on therapies for corneal epithelial and endothelial diseases that have already been regulatory approved as regenerative therapy products. The applications of regenerative therapy to the corneal epithelium were attempted and confirmed earlier than other parts of the cornea, following advancements in basic research on corneal epithelial stem cells. Based on these advances, four regenerative therapy products for corneal epithelial disease, each employing distinct cell sources and culture techniques, have been commercialized since the regulatory approval of Holoclar® in Italy as a regenerative therapy product for corneal epithelial disease in 2015. Corneal endothelial regenerative therapy was started by the development of an in vitro method to expand corneal endothelial cells which do not proliferate in adults. The product was approved in Japan as Vyznova® in 2023. The development of regenerative therapies for retinal and ocular surface diseases is actively being pursued, and these therapies use somatic stem cells and pluripotent stem cells (PSCs), especially induced pluripotent stem cells (iPSCs). Accordingly, the eye field is anticipated to play a pioneering role in regenerative therapy development going forward.

在已投入临床应用的再生疗法中,角膜再生疗法是最先进的领域之一,已有多个产品获得监管部门批准。本文介绍了眼科领域从最初开发到临床应用的进展情况,尤其重点介绍了已获得监管部门批准作为再生疗法产品的角膜上皮和内皮疾病疗法。随着角膜上皮干细胞基础研究的进展,角膜上皮再生疗法的应用比角膜其他部位更早得到尝试和证实。基于这些进展,自 2015 年 Holoclar® 作为角膜上皮疾病再生疗法产品在意大利获得监管部门批准以来,已有四种角膜上皮疾病再生疗法产品实现了商业化,每种产品都采用了不同的细胞来源和培养技术。角膜内皮再生疗法是通过开发一种体外方法来扩增成人不增殖的角膜内皮细胞而开始的。该产品于 2023 年在日本获得批准,命名为 Vyznova®。目前正在积极开发治疗视网膜和眼表疾病的再生疗法,这些疗法使用体细胞干细胞和多能干细胞(PSC),特别是诱导多能干细胞(iPSC)。因此,眼科领域有望在未来的再生疗法发展中发挥先锋作用。
{"title":"Status and prospects for the development of regenerative therapies for corneal and ocular diseases","authors":"Hiroshi Takayanagi ,&nbsp;Ryuhei Hayashi","doi":"10.1016/j.reth.2024.09.001","DOIUrl":"10.1016/j.reth.2024.09.001","url":null,"abstract":"<div><p>Among the regenerative therapies being put into clinical use, the field of corneal regenerative therapy is one of the most advanced, with several regulatory approved products. This article describes the progress from initial development through to clinical application in the eye field, with a particular focus on therapies for corneal epithelial and endothelial diseases that have already been regulatory approved as regenerative therapy products. The applications of regenerative therapy to the corneal epithelium were attempted and confirmed earlier than other parts of the cornea, following advancements in basic research on corneal epithelial stem cells. Based on these advances, four regenerative therapy products for corneal epithelial disease, each employing distinct cell sources and culture techniques, have been commercialized since the regulatory approval of Holoclar® in Italy as a regenerative therapy product for corneal epithelial disease in 2015. Corneal endothelial regenerative therapy was started by the development of an <em>in vitro</em> method to expand corneal endothelial cells which do not proliferate in adults. The product was approved in Japan as Vyznova® in 2023. The development of regenerative therapies for retinal and ocular surface diseases is actively being pursued, and these therapies use somatic stem cells and pluripotent stem cells (PSCs), especially induced pluripotent stem cells (iPSCs). Accordingly, the eye field is anticipated to play a pioneering role in regenerative therapy development going forward.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 819-825"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001627/pdfft?md5=f847733a1503529e24332b9703c41d32&pid=1-s2.0-S2352320424001627-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo biocompatibility assessment of 3D printed bioresorbable polymers for brain tissue regeneration. A feasibility study 用于脑组织再生的 3D 打印生物可吸收聚合物的体内生物相容性评估。可行性研究
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.10.004
Julien Clauzel , Nina Colitti , Maylis Combeau , Wafae Labriji , Lorenne Robert , Adrien Brilhault , Carla Cirillo , Franck Desmoulin , Isabelle Raymond-Letron , Isabelle Loubinoux

Introduction

The limited capacity of brain tissue to regenerate after acute injury, hampered by cell death, edema and inflammation, has led to an interest in promising and innovative approaches such as implantable regenerative scaffolds designed to improve brain plasticity. Leveraging the capabilities of bioprinting, these scaffolds can be tailored to match the intricate architecture of the brain.

Methods

In this methodological study, we performed in vivo biocompatibility assessments after a brain lesion on three distinct bioeliminable or bioresorbable materials: Poly(ethylene glycol) diacrylate (PEGDA), Polycaprolactone (PCL) and a PEGDA mixed with gelatin methacrylate (PEGDA-GelMA).

Results

A scaffold with a complex shape was printed with patterns, spatial resolution and porosity adapted to cerebral cortex reconstruction. In vivo evaluations were complemented by behavioral monitoring, affirming the safety of these materials. High-resolution T2 MRI imaging effectively captured scaffold structures and demonstrated their non-invasive utility in monitoring degradability. ASL MRI imaging quantified cerebral blood flow and was positively and significantly correlated with lectin immunofluorescent labeling. It may be used to non-invasively monitor progressive revascularization of implants.
PEGDA produced an intense foreign-body response, encapsulated by a fibro-inflammatory barrier. On the other hand, PCL provoked a controlled inflammatory reaction and facilitated cell migration into the scaffold, although it induced a fibrotic response around PCL fibers. Conversely, the PEGDA-GelMA composite emerged as a promising candidate for intracerebral implantation. It facilitated the creation of a permissive glial layer, while also inducing neovascularization and attracting neuronal progenitors.

Conclusion

Behavior, MRI monitoring and histology allowed a thorough following of biomaterial biocompatibility. The collective findings position PEGDA-GelMA as a convincing biomaterial option as a basis for treating severe brain lesions, offering new avenues in the search for effective treatments.
引言由于细胞死亡、水肿和炎症等因素的影响,脑组织在急性损伤后的再生能力有限,因此人们开始关注前景广阔的创新方法,如旨在改善大脑可塑性的可植入再生支架。在这项方法学研究中,我们在脑损伤后对三种不同的生物可消化或生物可吸收材料进行了体内生物相容性评估:结果印制出了具有复杂形状的支架,其图案、空间分辨率和孔隙率均适合大脑皮层的重建。体内评估与行为监测相辅相成,证实了这些材料的安全性。高分辨率 T2 核磁共振成像有效捕捉了支架结构,并证明了其在监测降解性方面的无创实用性。ASL MRI 成像可量化脑血流,并与凝集素免疫荧光标记呈显著正相关。ASL MRI 成像可量化脑血流,并与凝集素免疫荧光标记呈显著正相关,可用于无创监测植入物的逐步血管再通。另一方面,PCL 会引发受控的炎症反应,并促进细胞迁移到支架中,但会在 PCL 纤维周围引起纤维化反应。相反,PEGDA-GelMA 复合材料成为脑内植入的理想候选材料。结论通过行为学、核磁共振成像监测和组织学研究,可以全面了解生物材料的生物相容性。这些研究结果使 PEGDA-GelMA 成为治疗严重脑损伤的一种令人信服的生物材料,为寻找有效的治疗方法提供了新的途径。
{"title":"In vivo biocompatibility assessment of 3D printed bioresorbable polymers for brain tissue regeneration. A feasibility study","authors":"Julien Clauzel ,&nbsp;Nina Colitti ,&nbsp;Maylis Combeau ,&nbsp;Wafae Labriji ,&nbsp;Lorenne Robert ,&nbsp;Adrien Brilhault ,&nbsp;Carla Cirillo ,&nbsp;Franck Desmoulin ,&nbsp;Isabelle Raymond-Letron ,&nbsp;Isabelle Loubinoux","doi":"10.1016/j.reth.2024.10.004","DOIUrl":"10.1016/j.reth.2024.10.004","url":null,"abstract":"<div><h3>Introduction</h3><div>The limited capacity of brain tissue to regenerate after acute injury, hampered by cell death, edema and inflammation, has led to an interest in promising and innovative approaches such as implantable regenerative scaffolds designed to improve brain plasticity. Leveraging the capabilities of bioprinting, these scaffolds can be tailored to match the intricate architecture of the brain.</div></div><div><h3>Methods</h3><div>In this methodological study, we performed in vivo biocompatibility assessments after a brain lesion on three distinct bioeliminable or bioresorbable materials: Poly(ethylene glycol) diacrylate (PEGDA), Polycaprolactone (PCL) and a PEGDA mixed with gelatin methacrylate (PEGDA-GelMA).</div></div><div><h3>Results</h3><div>A scaffold with a complex shape was printed with patterns, spatial resolution and porosity adapted to cerebral cortex reconstruction. In vivo evaluations were complemented by behavioral monitoring, affirming the safety of these materials. High-resolution T2 MRI imaging effectively captured scaffold structures and demonstrated their non-invasive utility in monitoring degradability. ASL MRI imaging quantified cerebral blood flow and was positively and significantly correlated with lectin immunofluorescent labeling. It may be used to non-invasively monitor progressive revascularization of implants.</div><div>PEGDA produced an intense foreign-body response, encapsulated by a fibro-inflammatory barrier. On the other hand, PCL provoked a controlled inflammatory reaction and facilitated cell migration into the scaffold, although it induced a fibrotic response around PCL fibers. Conversely, the PEGDA-GelMA composite emerged as a promising candidate for intracerebral implantation. It facilitated the creation of a permissive glial layer, while also inducing neovascularization and attracting neuronal progenitors.</div></div><div><h3>Conclusion</h3><div>Behavior, MRI monitoring and histology allowed a thorough following of biomaterial biocompatibility. The collective findings position PEGDA-GelMA as a convincing biomaterial option as a basis for treating severe brain lesions, offering new avenues in the search for effective treatments.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 941-955"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023 关于先进 CAR-T 细胞产品、基于 AAV 的基因疗法以及细胞和基因疗法医疗护理/实践的监管见解:第六届亚洲再生医学合作会议报告--2023 年 4 月 20 日
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.09.015
Hiroshi Karasawa , Hirokuni Mizoguchi , Bryan Choi , Chia-Ling Hsieh , Masaaki Miyano , Yuu Moriya , Sasikumar Muthusamy , Koji Takakura , Kunihiko Suzuki , Yoshie Tsurumaki , Takeshi Watanabe , Karen Wen , Tomohiro Yoneda , Ta-Tung Yuan , Masayuki Nomura
The 6th Asia Partnership Conference of Regenerative Medicine (APACRM) was held in person with online on April 20, 2023, to promote the regulatory harmonization of regenerative medicine products throughout Asia. Recognizing domestic regulatory guidelines within each country and region and the underlying rationales are important initial steps toward harmonizing regulations. The 6th APACRM featured an open dialog regarding non-clinical evaluation for advanced CAR-T products, regulation of clinical trials for AAV-based gene therapies, and cell and gene therapies provided to patients as medical care/medical practices without market authorization through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine in each country and region are introduced. This paper summarizes the proceedings of the 6th APACRM for public dissemination to foster future discussions.
第六届亚洲再生医学合作大会(APACRM)于 2023 年 4 月 20 日在线举行,旨在促进整个亚洲地区再生医学产品的监管协调。认识每个国家和地区的国内监管准则及其基本原理是实现监管协调的重要第一步。在第六届亚太再生医学大会上,与会代表就先进 CAR-T 产品的非临床评估、基于 AAV 的基因疗法的临床试验监管,以及未经市场授权作为医疗保健/医疗行为提供给患者的细胞和基因疗法等问题进行了开放式对话。会议还介绍了各个国家和地区再生医学的最新进展。本文总结了第六届亚太再生医学大会的会议情况,以便向公众传播,促进未来的讨论。
{"title":"Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023","authors":"Hiroshi Karasawa ,&nbsp;Hirokuni Mizoguchi ,&nbsp;Bryan Choi ,&nbsp;Chia-Ling Hsieh ,&nbsp;Masaaki Miyano ,&nbsp;Yuu Moriya ,&nbsp;Sasikumar Muthusamy ,&nbsp;Koji Takakura ,&nbsp;Kunihiko Suzuki ,&nbsp;Yoshie Tsurumaki ,&nbsp;Takeshi Watanabe ,&nbsp;Karen Wen ,&nbsp;Tomohiro Yoneda ,&nbsp;Ta-Tung Yuan ,&nbsp;Masayuki Nomura","doi":"10.1016/j.reth.2024.09.015","DOIUrl":"10.1016/j.reth.2024.09.015","url":null,"abstract":"<div><div>The 6th Asia Partnership Conference of Regenerative Medicine (APACRM) was held in person with online on April 20, 2023, to promote the regulatory harmonization of regenerative medicine products throughout Asia. Recognizing domestic regulatory guidelines within each country and region and the underlying rationales are important initial steps toward harmonizing regulations. The 6th APACRM featured an open dialog regarding non-clinical evaluation for advanced CAR-T products, regulation of clinical trials for AAV-based gene therapies, and cell and gene therapies provided to patients as medical care/medical practices without market authorization through presentations from the industry and panel discussions with regulatory agencies. The latest updates on regenerative medicine in each country and region are introduced. This paper summarizes the proceedings of the 6th APACRM for public dissemination to foster future discussions.</div></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 967-980"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The therapeutic effect of sufficient oxygen-rich PRP injection in facial rejuvenation by multiple objective evaluations in 26 cases 通过对 26 个病例的多重客观评估,充分富氧 PRP 注射对面部年轻化的治疗效果
IF 4.3 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.05.013
Jianyun Lu , Tong Zhang , Lu Zhou , Xiaoliang Tong , Rong Gui , Ling Jiang , Zhen Tang , Yunfeng Fu , Guosheng Zhao , Jinrong Zeng , Lihua Gao

Background

Ozone can enhance the expression of some growth factors (GFs) in platelet rich plasma (PRP), recent study showed oxygen-rich PRP (ozonized PRP) have better therapeutic effects on bone and joint diseases. PRP injection has been widely used in the treatment of facial rejuvenation, but the efficacy of sufficient oxygen-rich PRP in facial rejuvenation has not been studied.

Objective

Firstly, we examined whether ozone treatment can increase the concentration of GFs of PRP in vitro. And then a variety of subjective and objective detection methods were used to evaluate the effect of sufficient(10–12 mL each time for the injection of face and neck) oxygen-rich (ozonized PRP) PRP injection in facial rejuvenation by follow-up for 6 months. At last, we investigated the satisfaction, side effects and pain score of the treatment through a questionnaire survey.

Methods

The concentration of main GFs in PRP treated with different dose of ozone in vitro was measured by ELISA. Clinical picture, the collagen thickness of dermis by reflectance confocal microscope(RCM), skin conditions (including spots, ultraviolet (UV) spots, brown spots, red area, pores, wrinkles, texture and porphyrin) by VISIA were collected before treatment and each month follow-up visit after treatment until 6-month follow-up period was finished. Patients’ satisfaction, side effects and pain score were collected at the end of follow-up period.

Results

PRP treated by high-dose ozone (57 μg/mL, ozone/PRP volume ratio:1/1) in vitro showed a significant increase in endothelial growth factor (EGF) and transforming growth factor-β (TGF-β) compared to baseline(P < 0.05). Collagen thickness of forehead, cheek and neck improved significantly compare to the baseline until to the 6 months after treatment. Spots, UV spots, brown spots, red area and texture improved significantly compare to the baseline(P < 0.05). All of participants reported improvement and have a median pain score of 4.19. No serious adverse events were observed.

Conclusions

Ozone treatment can increase the concentration of GFs such as EGF and TGF-β in PRP in vitro. Sufficient oxygen-rich PRP injection may be an effective and promising method to treat facial rejuvenation.

背景臭氧能增强富血小板血浆(PRP)中某些生长因子(GFs)的表达,最近的研究表明富氧PRP(臭氧PRP)对骨关节疾病有更好的治疗效果。PRP注射已被广泛用于面部年轻化的治疗,但充分富氧的PRP在面部年轻化中的疗效尚未得到研究。然后采用多种主观和客观检测方法,通过为期 6 个月的随访,评估足量(面部和颈部每次注射 10-12 mL)富氧 PRP(臭氧 PRP)注射在面部年轻化中的效果。方法采用酶联免疫吸附法(ELISA)测定经不同剂量臭氧处理的 PRP 中主要 GFs 的浓度。收集治疗前的临床表现、反射共聚焦显微镜(RCM)检测的真皮层胶原蛋白厚度、VISIA检测的皮肤状况(包括色斑、紫外线斑、黄褐斑、红血丝、毛孔、皱纹、肤质和卟啉),治疗后每月随访,直至6个月随访期结束。结果 经高浓度臭氧(57 μg/mL,臭氧/卟啉体积比:1/1)体外治疗的卟啉显示,与基线相比,内皮生长因子(EGF)和转化生长因子-β(TGF-β)显著增加(P < 0.05)。额头、脸颊和颈部的胶原蛋白厚度与基线相比有明显改善,直至治疗后 6 个月。斑点、紫外线斑、黄褐斑、红斑和肤质与基线相比均有明显改善(P < 0.05)。所有参与者均表示病情有所改善,疼痛评分中位数为 4.19。结论臭氧治疗可提高体外 PRP 中 EGF 和 TGF-β 等 GFs 的浓度。充分富氧的 PRP 注射可能是治疗面部年轻化的一种有效且有前景的方法。
{"title":"The therapeutic effect of sufficient oxygen-rich PRP injection in facial rejuvenation by multiple objective evaluations in 26 cases","authors":"Jianyun Lu ,&nbsp;Tong Zhang ,&nbsp;Lu Zhou ,&nbsp;Xiaoliang Tong ,&nbsp;Rong Gui ,&nbsp;Ling Jiang ,&nbsp;Zhen Tang ,&nbsp;Yunfeng Fu ,&nbsp;Guosheng Zhao ,&nbsp;Jinrong Zeng ,&nbsp;Lihua Gao","doi":"10.1016/j.reth.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.reth.2024.05.013","url":null,"abstract":"<div><h3>Background</h3><p>Ozone can enhance the expression of some growth factors (GFs) in platelet rich plasma (PRP), recent study showed oxygen-rich PRP (ozonized PRP) have better therapeutic effects on bone and joint diseases. PRP injection has been widely used in the treatment of facial rejuvenation, but the efficacy of sufficient oxygen-rich PRP in facial rejuvenation has not been studied.</p></div><div><h3>Objective</h3><p>Firstly, we examined whether ozone treatment can increase the concentration of GFs of PRP in vitro. And then a variety of subjective and objective detection methods were used to evaluate the effect of sufficient(10–12 mL each time for the injection of face and neck) oxygen-rich (ozonized PRP) PRP injection in facial rejuvenation by follow-up for 6 months. At last, we investigated the satisfaction, side effects and pain score of the treatment through a questionnaire survey.</p></div><div><h3>Methods</h3><p>The concentration of main GFs in PRP treated with different dose of ozone in vitro was measured by ELISA. Clinical picture, the collagen thickness of dermis by reflectance confocal microscope(RCM), skin conditions (including spots, ultraviolet (UV) spots, brown spots, red area, pores, wrinkles, texture and porphyrin) by VISIA were collected before treatment and each month follow-up visit after treatment until 6-month follow-up period was finished. Patients’ satisfaction, side effects and pain score were collected at the end of follow-up period.</p></div><div><h3>Results</h3><p>PRP treated by high-dose ozone (57 μg/mL, ozone/PRP volume ratio:1/1) in vitro showed a significant increase in endothelial growth factor (EGF) and transforming growth factor-β (TGF-β) compared to baseline(<em>P</em> &lt; 0.05). Collagen thickness of forehead, cheek and neck improved significantly compare to the baseline until to the 6 months after treatment. Spots, UV spots, brown spots, red area and texture improved significantly compare to the baseline(<em>P</em> &lt; 0.05). All of participants reported improvement and have a median pain score of 4.19. No serious adverse events were observed.</p></div><div><h3>Conclusions</h3><p>Ozone treatment can increase the concentration of GFs such as EGF and TGF-β in PRP in vitro. Sufficient oxygen-rich PRP injection may be an effective and promising method to treat facial rejuvenation.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 213-218"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001007/pdfft?md5=1ff0a7a6ccfeadd3bdfc811c69bc41c9&pid=1-s2.0-S2352320424001007-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High efficiency protocol for platelet derived fibrin gel loaded with mesenchymal stromal cells extracellular vesicles 间充质基质细胞细胞外囊泡负载血小板衍生纤维蛋白凝胶的高效方案
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.06.020
Enrico Ragni , Paola De Luca , Simona Landoni , Federico Valli , Leonardo Mortati , Silvia Palombella , Giuseppe Talò , Matteo Moretti , Laura de Girolamo

Introduction

Extracellular vesicles from mesenchymal stromal cells (MSC-EVs) are potent stimulators of naïve cartilage and their injection is studied in clinical trials for cartilage lesions, since often cartilage repaired with conventional approaches is incomplete or less performant leading to joint degeneration. The main pitfall of these innovative approaches is the high EVs dispersion into the joint cavity and consequent low concentration at lesion site. Thus, biological scaffolds for concentration of EVs where needed might be a promising option. This work aimed at producing an enhanced platelet-derived fibrin gel loaded with adipose-derived MSCs (ASCs)-EVs.

Methods

EVs’ embedment efficiency in platelet gel, their release and incorporation in OA chondrocytes and cartilage explants were monitored by flow cytometry, microfluidic approaches, scansion electron microscopy and real-time quantitative multimodal nonlinear optics imaging. The effect of released EVs was tested in OA chondrocytes by gene expression studies.

Results

A protocol ensuring high incorporation EVs efficiency in platelet gels was defined, relying on a one-step modification of the standard procedure used in current clinical practice. Trapped EVs were released continuously for up to 4 weeks and uptaken in pathologic chondrocytes and cartilage explants. The release of the EVs-loaded platelet gel had stronger and synergic anti-inflammatory/matrix remodelling effects with respect to both EVs per se and unloaded gel released products.

Conclusions

These results suggest the feasibility of producing a platelet gel loaded with MSC-EVs at high efficiency that can be used as an enhanced tool to foster chondrocyte homeostasis, a key requisite for proper cartilage healing.

导言间充质干基质细胞(MSC-EVs)产生的细胞外囊泡是新生软骨的强效刺激剂,由于传统方法修复的软骨往往不完整或性能较差,导致关节退化,因此临床试验研究了注射间充质干基质细胞外囊泡治疗软骨损伤。这些创新方法的主要缺陷是 EVs 在关节腔中的高分散性,以及因此在病变部位的低浓度。因此,在需要的地方集中 EVs 的生物支架可能是一个很有前景的选择。本研究旨在制备一种负载有脂肪来源间充质干细胞(ASCs)-EVs的增强型血小板衍生纤维蛋白凝胶。方法通过流式细胞术、微流体方法、扫描电子显微镜和实时定量多模态非线性光学成像技术监测EVs在血小板凝胶中的嵌入效率、释放情况以及在OA软骨细胞和软骨外植体中的结合情况。通过基因表达研究检测了释放的 EVs 对 OA 软骨细胞的影响。结果 通过对目前临床实践中使用的标准程序进行一步修改,确定了一种可确保血小板凝胶中 EVs 高效结合的方案。被捕获的 EVs 被持续释放长达 4 周,并被病理软骨细胞和软骨外植体吸收。结论:这些结果表明了高效生产含有间充质干细胞-EVs的血小板凝胶的可行性,这种凝胶可用作促进软骨细胞稳态的增强工具,而软骨细胞稳态是软骨正常愈合的关键。
{"title":"High efficiency protocol for platelet derived fibrin gel loaded with mesenchymal stromal cells extracellular vesicles","authors":"Enrico Ragni ,&nbsp;Paola De Luca ,&nbsp;Simona Landoni ,&nbsp;Federico Valli ,&nbsp;Leonardo Mortati ,&nbsp;Silvia Palombella ,&nbsp;Giuseppe Talò ,&nbsp;Matteo Moretti ,&nbsp;Laura de Girolamo","doi":"10.1016/j.reth.2024.06.020","DOIUrl":"https://doi.org/10.1016/j.reth.2024.06.020","url":null,"abstract":"<div><h3>Introduction</h3><p>Extracellular vesicles from mesenchymal stromal cells (MSC-EVs) are potent stimulators of naïve cartilage and their injection is studied in clinical trials for cartilage lesions, since often cartilage repaired with conventional approaches is incomplete or less performant leading to joint degeneration. The main pitfall of these innovative approaches is the high EVs dispersion into the joint cavity and consequent low concentration at lesion site. Thus, biological scaffolds for concentration of EVs where needed might be a promising option. This work aimed at producing an enhanced platelet-derived fibrin gel loaded with adipose-derived MSCs (ASCs)-EVs.</p></div><div><h3>Methods</h3><p>EVs’ embedment efficiency in platelet gel, their release and incorporation in OA chondrocytes and cartilage explants were monitored by flow cytometry, microfluidic approaches, scansion electron microscopy and real-time quantitative multimodal nonlinear optics imaging. The effect of released EVs was tested in OA chondrocytes by gene expression studies.</p></div><div><h3>Results</h3><p>A protocol ensuring high incorporation EVs efficiency in platelet gels was defined, relying on a one-step modification of the standard procedure used in current clinical practice. Trapped EVs were released continuously for up to 4 weeks and uptaken in pathologic chondrocytes and cartilage explants. The release of the EVs-loaded platelet gel had stronger and synergic anti-inflammatory/matrix remodelling effects with respect to both EVs per se and unloaded gel released products.</p></div><div><h3>Conclusions</h3><p>These results suggest the feasibility of producing a platelet gel loaded with MSC-EVs at high efficiency that can be used as an enhanced tool to foster chondrocyte homeostasis, a key requisite for proper cartilage healing.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 442-457"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001275/pdfft?md5=9883c821b10a2bce31c3ec42b29b40a9&pid=1-s2.0-S2352320424001275-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wharton's jelly stem cells delivered via a curcumin-loaded nanofibrous wound dressings improved diabetic wound healing via upregulating VEGF and IGF genes: An in vitro and in vivo study 通过姜黄素纳米纤维伤口敷料输送的沃顿果冻干细胞可通过上调血管内皮生长因子和IGF基因改善糖尿病伤口愈合:体外和体内研究
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.06.018
Chengjin Chen , Hui Zhao , Wenlu Zhang , Xuelan Hong , Shengjie Li , Saeed Rohani

Diabetic wounds pose an enduring clinical hurdle, marked by delayed recovery, persistent inflammation, and an elevated susceptibility to infections. Conventional treatment approaches often fall short of delivering optimal outcomes, prompting the exploration of innovative methods to enhance the healing process. Electrospun wound dressings offer superior healing, controlled drug release, enhanced cell proliferation, biocompatibility, high surface area, and antimicrobial properties. In the current study, polycaprolactone/gelatin-based nanofibrous wound dressings were developed for the delivery of Wharton's jelly stem cells and curcumin into the diabetic wounds bed. Curcumin was loaded into the polycaprolactone/gelatin solution and electrospun to produce curcumin-loaded scaffolds. In vitro experiments including scanning electron microscopy, cell viability assay, release assay, hemocompatibility assay, cell proliferation assay, and antibacterial assay were utilized to characterize the delivery system. Then, curcumin-loaded scaffolds were seeded with 30,000 Wharton's jelly stem cells and implanted into a rat model of diabetic wounds. Study showed that the scaffolds containing both Wharton's jelly stem cells and curcumin significantly improved diabetic wound closure (86.32 3.88% at the end of 14th day), augmented collagen deposition, and improved epithelial tissue formation. Gene expression studies showed that VEGF and IGF genes were significantly upregulated by the co-delivery system. Our developed system may have augmented diabetic wound healing via upregulating pro-healing genes.

糖尿病伤口是一个持久的临床障碍,其特点是恢复延迟、炎症持续存在、易受感染。传统的治疗方法往往无法达到最佳效果,这就促使人们探索创新方法来加强伤口愈合过程。电纺伤口敷料具有优异的愈合能力、可控药物释放、增强细胞增殖、生物相容性、高表面积和抗菌特性。本研究开发了聚己内酯/明胶基纳米纤维伤口敷料,用于向糖尿病伤口床输送沃顿果冻干细胞和姜黄素。姜黄素被添加到聚己内酯/明胶溶液中,并通过电纺产生姜黄素负载支架。体外实验包括扫描电子显微镜、细胞活力检测、释放检测、血液相容性检测、细胞增殖检测和抗菌检测,以确定输送系统的特性。然后,在载姜黄素的支架上播种了 30,000 个沃顿果冻干细胞,并将其植入大鼠糖尿病伤口模型中。研究表明,含有沃顿果冻干细胞和姜黄素的支架能显著改善糖尿病伤口的闭合(第14天结束时闭合率为86.32 3.88%),增加胶原沉积,改善上皮组织的形成。基因表达研究表明,血管内皮生长因子和 IGF 基因在联合给药系统的作用下明显上调。我们开发的系统可能通过上调促愈合基因来促进糖尿病伤口愈合。
{"title":"Wharton's jelly stem cells delivered via a curcumin-loaded nanofibrous wound dressings improved diabetic wound healing via upregulating VEGF and IGF genes: An in vitro and in vivo study","authors":"Chengjin Chen ,&nbsp;Hui Zhao ,&nbsp;Wenlu Zhang ,&nbsp;Xuelan Hong ,&nbsp;Shengjie Li ,&nbsp;Saeed Rohani","doi":"10.1016/j.reth.2024.06.018","DOIUrl":"10.1016/j.reth.2024.06.018","url":null,"abstract":"<div><p>Diabetic wounds pose an enduring clinical hurdle, marked by delayed recovery, persistent inflammation, and an elevated susceptibility to infections. Conventional treatment approaches often fall short of delivering optimal outcomes, prompting the exploration of innovative methods to enhance the healing process. Electrospun wound dressings offer superior healing, controlled drug release, enhanced cell proliferation, biocompatibility, high surface area, and antimicrobial properties. In the current study, polycaprolactone/gelatin-based nanofibrous wound dressings were developed for the delivery of Wharton's jelly stem cells and curcumin into the diabetic wounds bed. Curcumin was loaded into the polycaprolactone/gelatin solution and electrospun to produce curcumin-loaded scaffolds. In vitro experiments including scanning electron microscopy, cell viability assay, release assay, hemocompatibility assay, cell proliferation assay, and antibacterial assay were utilized to characterize the delivery system. Then, curcumin-loaded scaffolds were seeded with 30,000 Wharton's jelly stem cells and implanted into a rat model of diabetic wounds. Study showed that the scaffolds containing both Wharton's jelly stem cells and curcumin significantly improved diabetic wound closure (86.32 3.88% at the end of 14th day), augmented collagen deposition, and improved epithelial tissue formation. Gene expression studies showed that VEGF and IGF genes were significantly upregulated by the co-delivery system. Our developed system may have augmented diabetic wound healing via upregulating pro-healing genes.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 547-556"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001263/pdfft?md5=e3b1d760f124180ff507600d7d5d875e&pid=1-s2.0-S2352320424001263-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regenerative medicine in Obstetrics & Gynecology: Current status under the Act on the Safety of Regenerative Medicine in Japan 妇产科中的再生医学:日本再生医学安全法的现状
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.08.003
Satoshi Hosoya , Sena Awano-Kim , Ryo Yokomizo , Yuichiro Ukon , Kazuki Morita , Yuta Kasahara , Hiroshi Kishi , Aikou Okamoto

Introduction

While the provision of unapproved regenerative medicine has been problematic worldwide, few studies have examined the implementation status of regenerative medicine (RM) in the specific field. This study aimed to determine the current status of therapy and clinical research in the obstetrics and gynecology (OBGYN) in Japan under the Act on the Safety of Regenerative Medicine (RM Act).

Methods

Detailed data were extracted from publicly available websites provided by the Ministry of Health, Labour, and Welfare. We extracted descriptive details, including risk classification of the RM Act, modality, target disease, locality, institution, and administration route. For therapy, the price for each modality was evaluated.

Results

The total number of therapeutic provision plans in OBGYN (1.9% of RM in Japan) are classified as Class II (moderate) risk. Most were administered in clinics in urban areas for treating endometrial or ovarian infertility by locally administering platelet-rich plasma (PRP) or autologous mesenchymal stem cells (MSCs). The price using MSCs is approximately eight times more expensive that of those involving PRP (1832.1 ± 1139.8 vs 240.8 ± 106.5 thousand yen, p < 0.0001). Regarding research, four plans (2.2%) were submitted to target implantation failure and advanced gynecological cancer using autologous lymphocytes, dendritic cells, or MSCs.

Conclusion

The RM Act permits knowledge of the current status of regenerative medicine even for unapproved uses in a specific clinical field. The study findings shall prompt a worldwide discussion regarding the required regulations for therapy and clinical research of RM.

导言虽然提供未经批准的再生医学在世界范围内一直是个问题,但很少有研究对再生医学(RM)在特定领域的实施状况进行调查。本研究旨在根据《再生医学安全法》(RM 法)确定日本妇产科(OBGYN)的治疗和临床研究现状。方法从厚生劳动省提供的公开网站上提取详细数据。我们提取了描述性细节,包括《再生医学法案》的风险分类、模式、目标疾病、地区、机构和给药途径。结果妇产科的治疗供应计划(占日本 RM 的 1.9%)被归类为二级(中度)风险。大多数计划在城市地区的诊所实施,通过局部注射富血小板血浆(PRP)或自体间充质干细胞(MSCs)治疗子宫内膜或卵巢不孕症。使用间充质干细胞的价格大约是使用富血小板血浆价格的八倍(1832.1 ± 1139.8 vs 240.8 ± 106.5 万日元,p < 0.0001)。在研究方面,提交了四项计划(2.2%),使用自体淋巴细胞、树突状细胞或间叶干细胞,针对植入失败和晚期妇科癌症进行研究。研究结果将促使全世界就再生医学治疗和临床研究的必要法规展开讨论。
{"title":"Regenerative medicine in Obstetrics & Gynecology: Current status under the Act on the Safety of Regenerative Medicine in Japan","authors":"Satoshi Hosoya ,&nbsp;Sena Awano-Kim ,&nbsp;Ryo Yokomizo ,&nbsp;Yuichiro Ukon ,&nbsp;Kazuki Morita ,&nbsp;Yuta Kasahara ,&nbsp;Hiroshi Kishi ,&nbsp;Aikou Okamoto","doi":"10.1016/j.reth.2024.08.003","DOIUrl":"10.1016/j.reth.2024.08.003","url":null,"abstract":"<div><h3>Introduction</h3><p>While the provision of unapproved regenerative medicine has been problematic worldwide, few studies have examined the implementation status of regenerative medicine (RM) in the specific field. This study aimed to determine the current status of therapy and clinical research in the obstetrics and gynecology (OBGYN) in Japan under the Act on the Safety of Regenerative Medicine (RM Act).</p></div><div><h3>Methods</h3><p>Detailed data were extracted from publicly available websites provided by the Ministry of Health, Labour, and Welfare. We extracted descriptive details, including risk classification of the RM Act, modality, target disease, locality, institution, and administration route. For therapy, the price for each modality was evaluated.</p></div><div><h3>Results</h3><p>The total number of therapeutic provision plans in OBGYN (1.9% of RM in Japan) are classified as Class II (moderate) risk. Most were administered in clinics in urban areas for treating endometrial or ovarian infertility by locally administering platelet-rich plasma (PRP) or autologous mesenchymal stem cells (MSCs). The price using MSCs is approximately eight times more expensive that of those involving PRP (1832.1 ± 1139.8 vs 240.8 ± 106.5 thousand yen, p &lt; 0.0001). Regarding research, four plans (2.2%) were submitted to target implantation failure and advanced gynecological cancer using autologous lymphocytes, dendritic cells, or MSCs.</p></div><div><h3>Conclusion</h3><p>The RM Act permits knowledge of the current status of regenerative medicine even for unapproved uses in a specific clinical field. The study findings shall prompt a worldwide discussion regarding the required regulations for therapy and clinical research of RM.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 564-570"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001391/pdfft?md5=03dca65353bf40aa19ebdbb6e87d1e11&pid=1-s2.0-S2352320424001391-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing engineered muscle tissues utilizing standard cell culture plates and mesenchymal stem cell-conditioned medium 利用标准细胞培养板和间充质干细胞调节培养基开发工程肌肉组织
IF 3.4 3区 环境科学与生态学 Q3 CELL & TISSUE ENGINEERING Pub Date : 2024-06-01 DOI: 10.1016/j.reth.2024.08.011
Yihao Wen , Jia Tian , Juan Li , Xiangming Na , Ziyi Yu , Weiqing Zhou

The construction of engineered muscle tissues that resemble the function and microstructure of human muscles holds significant promise for various applications, including disease modeling, regenerative medicine, and biological machines. However, current muscle tissue engineering approaches often rely on complex equipment which may limit their accessibility and practicality. Herein, we present a convenient approach using a standard 24-well cell culture plate to construct a platform to facilitate engineered muscle tissues formation and culture. Using this platform, engineered muscle tissue with differentiation characteristics can be manufactured in large quantities. Additionally, the mesenchymal stem cell conditioned medium was utilized to promote the formation and functionality of the engineered muscle tissues. The resulting tissues comprised a higher cell density and a better differentiation effect in the tissues. Taken together, this study provides a simple, convenient, and effective platform for studying muscle tissue engineering.

构建与人体肌肉功能和微观结构相似的工程肌肉组织,在疾病建模、再生医学和生物机器等各种应用领域大有可为。然而,目前的肌肉组织工程方法往往依赖于复杂的设备,这可能会限制其可及性和实用性。在此,我们提出一种便捷的方法,利用标准的 24 孔细胞培养板构建一个平台,以促进工程肌肉组织的形成和培养。利用这一平台,可以大量制造具有分化特征的工程肌肉组织。此外,还利用间充质干细胞条件培养基促进工程肌肉组织的形成和功能。由此产生的组织具有更高的细胞密度和更好的组织分化效果。总之,这项研究为研究肌肉组织工程提供了一个简单、方便、有效的平台。
{"title":"Developing engineered muscle tissues utilizing standard cell culture plates and mesenchymal stem cell-conditioned medium","authors":"Yihao Wen ,&nbsp;Jia Tian ,&nbsp;Juan Li ,&nbsp;Xiangming Na ,&nbsp;Ziyi Yu ,&nbsp;Weiqing Zhou","doi":"10.1016/j.reth.2024.08.011","DOIUrl":"10.1016/j.reth.2024.08.011","url":null,"abstract":"<div><p>The construction of engineered muscle tissues that resemble the function and microstructure of human muscles holds significant promise for various applications, including disease modeling, regenerative medicine, and biological machines. However, current muscle tissue engineering approaches often rely on complex equipment which may limit their accessibility and practicality. Herein, we present a convenient approach using a standard 24-well cell culture plate to construct a platform to facilitate engineered muscle tissues formation and culture. Using this platform, engineered muscle tissue with differentiation characteristics can be manufactured in large quantities. Additionally, the mesenchymal stem cell conditioned medium was utilized to promote the formation and functionality of the engineered muscle tissues. The resulting tissues comprised a higher cell density and a better differentiation effect in the tissues. Taken together, this study provides a simple, convenient, and effective platform for studying muscle tissue engineering.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 683-692"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001482/pdfft?md5=e4f0ae84a7a76d08342f88460fc8a953&pid=1-s2.0-S2352320424001482-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Regenerative Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1